Residency · Chicago, IL
Sponsored by McGaw Medical Center of Northwestern University
Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial.
The Lancet. Child & adolescent health · 2024 · 64 citations · Joel Charrow
Cystic Fibrosis Foundation Evidence-Based Guideline for the Management of CRMS/CFSPID.
Pediatrics · 2024 · 28 citations · Angelique Mercier
Persistent growth-promoting effects of vosoritide in children with achondroplasia are accompanied by improvements in physical and social aspects of health-related quality of life.
Genetics in medicine : official journal of the American College of Medical Genetics · 2024 · 20 citations · Carlos Prada
Sustained growth-promoting effects of vosoritide in children with achondroplasia from an ongoing phase 3 extension study.
Med (New York, N.Y.) · 2025 · 20 citations · Carlos Prada
The diagnosis and management of Gaucher disease in pediatric patients: Where do we go from here?
Molecular genetics and metabolism · 2022 · 52 citations · Carlos Prada
Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study.
Genetics in medicine : official journal of the American College of Medical Genetics · 2021 · 82 citations ·
Efficacy and safety of empagliflozin in glycogen storage disease type Ib: Data from an international questionnaire.
Genetics in medicine : official journal of the American College of Medical Genetics · 2022 · 58 citations · Erika Vucko
Role of CAMK2D in neurodevelopment and associated conditions.
American journal of human genetics · 2024 · 27 citations · Carlos Prada